These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 2297773)
21. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Gallo JM; Brennan J; Hamilton TC; Halbherr T; Laub PB; Ozols RF; O'Dwyer PJ Cancer Res; 1995 Oct; 55(20):4507-11. PubMed ID: 7553617 [TBL] [Abstract][Full Text] [Related]
22. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. Friedman HS; Colvin OM; Griffith OW; Lippitz B; Elion GB; Schold SC; Hilton J; Bigner DD J Natl Cancer Inst; 1989 Apr; 81(7):524-7. PubMed ID: 2921776 [TBL] [Abstract][Full Text] [Related]
23. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. Lacreta FP; Brennan JM; Hamilton TC; Ozols RF; O'Dwyer PJ Drug Metab Dispos; 1994; 22(6):835-42. PubMed ID: 7895599 [TBL] [Abstract][Full Text] [Related]
24. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653 [TBL] [Abstract][Full Text] [Related]
25. The effect of L-buthionine-[S,R]-sulfoximine on the pancreas in mice. A model of weakening glutathione-based defense mechanisms. Lüthen RE; Neuschwander-Tetri BA; Niederau C; Ferrell LD; Grendell JH Int J Pancreatol; 1994 Aug; 16(1):31-6. PubMed ID: 7528760 [TBL] [Abstract][Full Text] [Related]
26. Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Yao K; Godwin AK; Ozols RF; Hamilton TC; O'Dwyer PJ Cancer Res; 1993 Aug; 53(16):3662-6. PubMed ID: 8101766 [TBL] [Abstract][Full Text] [Related]
27. Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas. Groothuis DR; Fischer JM; Pasternak JF; Blasberg RG; Vick NA; Bigner DD Cancer Res; 1983 Jul; 43(7):3368-73. PubMed ID: 6850641 [TBL] [Abstract][Full Text] [Related]
29. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells. Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Neuwelt EA; Pagel MA; Hasler BP; Deloughery TG; Muldoon LL Cancer Res; 2001 Nov; 61(21):7868-74. PubMed ID: 11691805 [TBL] [Abstract][Full Text] [Related]
31. Transport into brain of buthionine sulfoximine, an inhibitor of glutathione synthesis, is facilitated by esterification and administration of dimethylsulfoxide. Steinherz R; Mårtensson J; Wellner D; Meister A Brain Res; 1990 Jun; 518(1-2):115-9. PubMed ID: 2390716 [TBL] [Abstract][Full Text] [Related]
32. Enhancement of murine phenytoin teratogenicity by the gamma-glutamylcysteine synthetase inhibitor L-buthionine-(S,R)-sulfoximine and by the glutathione depletor diethyl maleate. Wong M; Helston LM; Wells PG Teratology; 1989 Aug; 40(2):127-41. PubMed ID: 2772848 [TBL] [Abstract][Full Text] [Related]
33. Photodynamic therapy with photofrin in combination with Buthionine Sulfoximine (BSO) of human glioma in the nude rat. Jiang F; Robin AM; Katakowski M; Tong L; Espiritu M; Singh G; Chopp M Lasers Med Sci; 2003; 18(3):128-33. PubMed ID: 14505195 [TBL] [Abstract][Full Text] [Related]
35. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery. Bertsche U; Schorn H Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339 [TBL] [Abstract][Full Text] [Related]
36. Lack of enhanced myelotoxicity with buthionine sulfoximine and sulfhydryl-dependent anticancer agents in mice. Soble MJ; Dorr RT Res Commun Chem Pathol Pharmacol; 1987 Feb; 55(2):161-80. PubMed ID: 3823607 [TBL] [Abstract][Full Text] [Related]
37. L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when administered locally in a rat glioma model. Sipos EP; Witham TF; Ratan R; Burger PC; Baraban J; Li KW; Piantadosi S; Brem H Neurosurgery; 2001 Feb; 48(2):392-400. PubMed ID: 11220384 [TBL] [Abstract][Full Text] [Related]
38. Glutathione depletion, radiosensitization, and misonidazole potentiation in hypoxic Chinese hamster ovary cells by buthionine sulfoximine. Clark EP; Epp ER; Biaglow JE; Morse-Gaudio M; Zachgo E Radiat Res; 1984 May; 98(2):370-80. PubMed ID: 6539482 [TBL] [Abstract][Full Text] [Related]
39. Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine. Saikawa Y; Kubota T; Kuo TH; Furukawa T; Tanino H; Watanabe M; Ishibiki K; Kitajima M Jpn J Cancer Res; 1993 Jul; 84(7):787-93. PubMed ID: 8370654 [TBL] [Abstract][Full Text] [Related]
40. Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. Allalunis-Turner MJ; Day RS; McKean JD; Petruk KC; Allen PB; Aronyk KE; Weir BK; Huyser-Wierenga D; Fulton DS; Urtasun RC J Neurooncol; 1991 Oct; 11(2):157-64. PubMed ID: 1744683 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]